CeriBell (NASDAQ:CBLL) Director Joseph Michael Taylor Sells 5,500 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 5,500 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $18.41, for a total transaction of $101,255.00. Following the sale, the director owned 61,573 shares of the company’s stock, valued at approximately $1,133,558.93. This represents a 8.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

CeriBell Trading Down 0.0%

CBLL traded down $0.01 during trading on Monday, hitting $18.47. 155,379 shares of the company’s stock were exchanged, compared to its average volume of 314,499. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $24.33. The stock has a 50 day moving average price of $18.98 and a 200 day moving average price of $19.70. The firm has a market cap of $700.56 million, a P/E ratio of -11.31 and a beta of 0.85.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $26.09 million. As a group, analysts expect that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CBLL has been the subject of several analyst reports. Canaccord Genuity Group decreased their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. raised its holdings in shares of CeriBell by 41.4% during the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after purchasing an additional 854 shares during the period. Sei Investments Co. lifted its position in CeriBell by 2.3% in the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock valued at $923,000 after purchasing an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the period. Deutsche Bank AG boosted its stake in CeriBell by 1.7% during the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the period. Finally, Strs Ohio acquired a new position in CeriBell during the 1st quarter valued at about $27,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.